Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines.
about
Vaccines against invasive Salmonella disease: current status and future directionsMeningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine: a new conjugate vaccine against invasive meningococcal diseasePneumococcal Vaccination in High-Risk Individuals: Are We Doing It Right?Review of meningococcal vaccines with updates on immunization in adultsTwo cases of hemolytic uremic syndrome caused by Streptococcus pneumoniae serotype 3, one being a vaccine failure.High incidence of septic shock caused by Streptococcus pneumoniae serotype 3--a retrospective epidemiological studyFifth Percentile Cutoff Values for Antipneumococcal Polysaccharide and Anti-Salmonella typhi Vi IgG Describe a Normal Polysaccharide ResponsePneumococcal polysaccharide abrogates conjugate-induced germinal center reaction and depletes antibody secreting cell pool, causing hyporesponsiveness.Critical appraisal of a quadrivalent CRM(197) conjugate vaccine against meningococcal serogroups A, C W-135 and Y (Menveo) in the context of treatment and prevention of invasive diseaseRecurrent severe invasive pneumococcal disease in an adult with previously unknown hyposplenia.Reduction of Streptococcus pneumoniae in upper respiratory tract cultures and a decreased incidence of related acute otitis media following introduction of childhood pneumococcal conjugate vaccines in a Swedish countyHigh-dimensional assessment of B-cell responses to quadrivalent meningococcal conjugate and plain polysaccharide vaccine.The immunogenicity and safety of an investigational meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (ACWY-TT) compared with a licensed meningococcal tetravalent polysaccharide vaccine: a randomized, controlled non-inferioritReduction of Streptococcus pneumoniae Colonization and Dissemination by a Nonopsonic Capsular Polysaccharide Antibody.Immunogenicity and safety of a quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) administered to adults aged 56 Years and older: results of an open-label, randomized, controlled trial.Recurrent Invasive Pneumococcal Disease Serotype 12F in a Vaccinated Splenectomized Patient.No long-term evidence of hyporesponsiveness after use of pneumococcal conjugate vaccine in children previously immunized with pneumococcal polysaccharide vaccinePersistence of the immune response two years after vaccination with quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in Asian adolescents.Issues in pediatric vaccine-preventable diseases in low- to middle-income countriesDevelopment of a glycoconjugate vaccine to prevent meningitis in Africa caused by meningococcal serogroup X.Pneumococcal immunization in immunocompromised hosts: where do we stand?B-1 lymphocytes in mice and nonhuman primates.Review of current typhoid fever vaccines, cross-protection against paratyphoid fever, and the European guidelines.Anti-Pneumococcal Vaccine-Induced Cellular Immune Responses in Post-Traumatic Splenectomized Individuals.Maternal and neonatal pneumococcal vaccination - where are we now?Vi capsular polysaccharide: Synthesis, virulence, and application.Specific and cross-reactive plasmablast response in humans after primary and secondary immunization with Vi capsular polysaccharide typhoid vaccine.Safety and immunogenicity of a Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study.[Medicinal prophylaxis during intensified immunosuppression in children and adolescents : part 2].Low immunogenicity of quadrivalent meningococcal vaccines in solid organ transplant recipients.Antigen-specific B-cell response to 13-valent pneumococcal conjugate vaccine in asplenic individuals with β-thalassemia previously immunized with 23-valent pneumococcal polysaccharide vaccine.Pneumococcal responses are similar in Papua New Guinean children aged 3-5 years vaccinated in infancy with pneumococcal polysaccharide vaccine with or without prior pneumococcal conjugate vaccine, or without pneumococcal vaccination.Splenectomy: reducing the risk of infection.[Pneumococcus vaccination in immunosuppressed patients: current recommendations].Repeat pneumococcal polysaccharide vaccination does not impair functional immune responses among Indigenous Australians.Randomized clinical trial of a single versus a double dose of 13-valent pneumococcal conjugate vaccine in adults 55 through 74 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.Understanding modern-day vaccines: what you need to know.Value of allohaemagglutinins in the diagnosis of a polysaccharide antibody deficiency.Combined meningococcal serogroup A and W135 outer-membrane vesicles activate cell-mediated immunity and long-term memory responses against non-covalent capsular polysaccharide A.Impfen bei Immundefizienz : Anwendungshinweise zu den von der Ständigen Impfkommission empfohlenen Impfungen(I) Grundlagenpapier.
P2860
Q27007088-58BFB56F-2B77-464D-B215-3B13FB18CF76Q27028161-CEC8E97E-0978-489D-BCE2-E740EC3CC658Q28070059-89E1081C-A547-4BE1-8DC1-3E8840EF13FFQ28828692-BC4BC917-5B1B-429C-9615-6D652BA34AE4Q33405004-ABB75627-FC84-406D-9C7E-26197061ED7AQ33589823-7D0B16B4-F77D-47F8-95A1-A16CB1F5844CQ33665323-B8BA9B7F-7293-4BF1-8D4B-426F48DF3818Q34998490-3CA52306-8AB0-4C39-9D19-044FAAB6DCEDQ35187182-E1E279EA-BF42-4850-95E2-F772EFF2ACDFQ35532366-36734F83-F2EA-413F-97C6-F5D7DBA1D0E4Q36101864-160988CC-CCC2-4B9B-873F-87F3BA2DE342Q36264198-D326A34C-F8A0-4184-8D43-060CDD8CC643Q36391883-E447A472-E355-446D-AB11-E9447C925FA5Q36548292-4318AE74-3A1A-4DCC-9A26-29FC2BCE50CEQ36791713-39B04144-B7ED-4DFD-8146-60EFA44AFB14Q36820038-041144B3-8FD7-4E89-9892-98F0115EDCB2Q36984795-26070BB1-1245-4131-ABD1-370110694DECQ37197065-8F020C4F-F986-40A9-B84E-1CA6387B49E7Q37264972-C10D5BD6-397D-4BD9-9A1D-B9CE7D6A00B3Q37340824-1A2ADC5F-7467-43C0-81A8-79CF4986C779Q38168902-98D21D6C-D3C1-496E-ABEA-C8FABB6F082AQ38452441-C98336B2-AF8D-456E-A43A-2F4B366BCF56Q38600784-C1094017-8C80-4686-9E86-0CE146D46C86Q38794969-9DCA4069-3E5A-45E0-99DA-31C05B6531B2Q38948154-8CF98854-CB93-4893-9EA3-202C132A43CFQ40079316-03368C43-2896-4F37-82CB-E5841A5B8330Q40147988-237D4D55-6321-4BC1-82B3-A6800E762785Q40160745-35CDBEA9-9701-4B82-A16B-80A362D52DE5Q40238572-A1B9AEEE-C640-49AC-99F7-6FE722E5AA86Q41488993-7A5D23A6-861D-4A3E-89A6-B33CDC2DDD6EQ42212979-82716686-F16A-4EA5-AC79-9D317428EFFDQ42701700-972E5FDF-34F6-411B-B4D0-9A8F25556D9BQ43274706-6DFAEADA-FA6F-4C98-B352-E403EB64B2A5Q44820384-B4534FA4-568F-4A9F-A5E2-EA337E6E7ECEQ46747995-9959228B-043C-4F09-A2CB-47E670F405F7Q47560381-FE6E9F41-4374-43BB-ACD5-5B75A475AD4AQ48238411-B33C5B65-527F-489E-8752-0A0DCBB1A3B6Q50455142-88EFE709-75B5-4AB0-A106-C8052B1BE7F4Q50901235-193BAFB2-27C0-441E-94DF-F8EDF4678B1AQ52839548-CDFD79ED-DE05-4E6C-AE85-1E6A50944665
P2860
Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Hyporesponsiveness and its cli ...... de or glycoconjugate vaccines.
@en
Hyporesponsiveness and its cli ...... de or glycoconjugate vaccines.
@nl
type
label
Hyporesponsiveness and its cli ...... de or glycoconjugate vaccines.
@en
Hyporesponsiveness and its cli ...... de or glycoconjugate vaccines.
@nl
prefLabel
Hyporesponsiveness and its cli ...... de or glycoconjugate vaccines.
@en
Hyporesponsiveness and its cli ...... de or glycoconjugate vaccines.
@nl
P2860
P356
P1476
Hyporesponsiveness and its cli ...... de or glycoconjugate vaccines.
@en
P2093
Jan Poolman
P2860
P304
P356
10.1586/ERV.11.8
P50
P577
2011-03-01T00:00:00Z